At a glance
- Originator Fornix BioSciences; Utrecht University
- Class Antiasthmatics; Immunotherapies; Peptides; Skin disorder therapies
- Mechanism of Action Immunoglobulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic asthma; Crohn's disease; Multiple sclerosis; Skin disorders
Most Recent Events
- 04 Oct 2007 F 991 licensed to Clinquest Group
- 17 Feb 2005 F 991 is available for licensing (http://www.fornix.nl)
- 16 Feb 2005 Phase-II clinical trials in Allergic asthma in Netherlands (unspecified route)